IDEAS

IDEAYA Biosciences is a precision medicine oncology company focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company specializes in synthetic lethality, an emerging field of precision medicine that targets specific genetic vulnerabilities in cancer cells. Their lead program, darovasertib, is a potent and selective PKC inhibitor being evaluated for the treatment of uveal melanoma and other GNAQ/11 mutation-driven cancers. IDEAYA's pipeline also includes inhibitors targeting PRMT5, POLQ, and WRN, aimed at addressing high unmet needs in various solid tumors. By integrating bioinformatics and translational biology, the company aims to deliver personalized cancer treatments that improve patient outcomes.